Revolution Medicines (RVMD) Return on Capital Employed (2020 - 2026)
Revolution Medicines (RVMD) posted quarterly Return on Capital Employed of 68.84% for Q1 2026, down 3457.0% year-over-year from 2.05% in Q1 2025, and down 17.19% quarter-over-quarter from 58.74% in Q4 2025.
Revolution Medicines (RVMD) Return on Capital Employed (2020 - 2026) Analysis & Trends
Revolution Medicines' Return on Capital Employed history runs 7 years deep, the most recent figure standing at 68.84% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 3457.0% year-over-year to 68.84%; the TTM figure through Mar 2026 stood at 68.84% (down 3457.0% YoY), while the FY2025 annual figure was 54.59%, down 2246.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 68.84%, down from 58.74% in the prior quarter.
- The five-year high for Return on Capital Employed was 29.23% in Q1 2024, with the low at 81.79% in Q3 2024.
- The 5-year median for Return on Capital Employed is 38.03% (2022), against an average of 43.88%.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed plunged 4269 bps in 2024, then soared 3230 bps in 2025.
- Revolution Medicines' Return on Capital Employed stood at 34.12% in 2022, then fell by 4 bps to 35.33% in 2023, then gained by 2 bps to 34.53% in 2024, then slumped by 70 bps to 58.74% in 2025, then dropped by 17 bps to 68.84% in 2026.
- Business Quant data shows RVMD's Return on Capital Employed at 68.84% in Q1 2026, 58.74% in Q4 2025, and 49.5% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -36.13% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -55.45% |
| Mar 31, 2026 | -68.84% |
| Dec 31, 2025 | -58.74% |
| Sep 30, 2025 | -49.50% |
| Jun 30, 2025 | -40.56% |
| Mar 31, 2025 | -34.27% |
| Dec 31, 2024 | -34.53% |
| Sep 30, 2024 | -81.79% |
| Jun 30, 2024 | -68.51% |
| Mar 31, 2024 | -29.23% |
| Dec 31, 2023 | -35.33% |
| Sep 30, 2023 | -39.10% |
| Jun 30, 2023 | -32.37% |
| Mar 31, 2023 | -31.02% |
| Dec 31, 2022 | -34.12% |
| Sep 30, 2022 | -38.03% |
| Jun 30, 2022 | -38.05% |
| Mar 31, 2022 | -31.94% |
| Dec 31, 2021 | -27.81% |
| Sep 30, 2021 | -24.08% |